Patents by Inventor Osamu Honmou
Osamu Honmou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240122988Abstract: The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.Type: ApplicationFiled: April 26, 2023Publication date: April 18, 2024Applicants: Sapporo Medical University, Nipro CorporationInventors: Osamu Honmou, Masanori Sasaki, Rie Maezawa, Shinichi Oka, Yuko Sasaki, Masahito Nakazaki, Toshihiko Yamashita
-
Publication number: 20230193206Abstract: Provided is a method for producing serum that exhibits improved cell proliferation activity. A method for producing serum for culturing mammalian cells, comprising: maintaining blood collected from a first mammal at a temperature between 15° C. and 25° C. for up to 48 hours and preparing serum from the blood.Type: ApplicationFiled: December 25, 2020Publication date: June 22, 2023Applicants: SAPPORO MEDICAL UNIVERSITY, NIPRO CORPORATIONInventors: Osamu Honmou, Yoshihiro Yoshikawa, Takanori Sambuichi, Naomi Morikawa, Kazunari Abe
-
Patent number: 11666601Abstract: The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.Type: GrantFiled: April 26, 2017Date of Patent: June 6, 2023Assignees: Sapporo Medical University, Nipro CorporationInventors: Osamu Honmou, Masanori Sasaki, Rie Maezawa, Shinichi Oka, Yuko Sasaki, Masahito Nakazaki, Toshihiko Yamashita
-
Patent number: 11426432Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.Type: GrantFiled: May 6, 2019Date of Patent: August 30, 2022Assignee: Sapporo Medical UniversityInventor: Osamu Honmou
-
Publication number: 20220133805Abstract: The present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the pharmaceutical composition comprises mesenchymal stem cells and is intravenously administered.Type: ApplicationFiled: March 13, 2020Publication date: May 5, 2022Applicants: Sapporo Medical University, Nipro CorporationInventors: Osamu HONMOU, Masanori SASAKI, Yuko SASAKI, Shinichi OKA, Masahito NAKAZAKI, Rie MAEZAWA
-
Publication number: 20220125850Abstract: The present invention relates to a pharmaceutical composition containing mesenchymal stem cells administered to a patient subjected to stenting. The present invention relates specifically to: a pharmaceutical composition for repairing and regenerating tissue, comprising mesenchymal stem cells, wherein the pharmaceutical composition is administered to a patient subjected to stenting; and the prevention of in-stent neointimal hyperplasia or in-stent restenosis with the pharmaceutical composition.Type: ApplicationFiled: February 7, 2020Publication date: April 28, 2022Applicants: Sapporo Medical University, Nipro CorporationInventors: Osamu HONMOU, Masanori SASAKI, Yuko SASAKI, Shinichi OKA, Masahito NAKAZAKI, Rie MAEZAWA
-
Publication number: 20210271062Abstract: An observation device includes a microscope. The microscope includes an illumination light beam source, an illumination optical system, and an observation optical system forming an optical image of an observation target from reflected light beams obtained by reflection of illumination light beams by the observation target. The observation optical system includes a phase plate changing the phase of directly reflected light beams reflected on a reflection surface among the reflected light beams. Both the illumination optical system and the observation optical system are arranged under the observation target. The observation device includes an image pickup device photoelectrically converting the optical image obtained by the observation optical system to create image data of the observation target and a display device displaying the image data. The illumination light beam emitted from the illumination optical system is a collimated light beam.Type: ApplicationFiled: July 4, 2019Publication date: September 2, 2021Inventors: Osamu HONMOU, Daiki TATEYAMA, Kosuke TAKAHASHI, Kosei TATEYAMA, Yoshihiro YOSHIKAWA
-
Publication number: 20200345781Abstract: The present invention relates to a cell-based medicine comprising mesenchymal stem cells, and a method for producing the same. More specifically, the present invention relates to: a cell-based medicine containing mesenchymal stem cells, wherein a) the mesenchymal stem cells express CX3CL1 under stimulation with an inflammatory cytokine, and/or b) 90% or more of the mesenchymal stem cells express EGFR and/or ITGA4; and a method for producing a cell-based medicine containing mesenchymal stem cells, the method comprising the steps of: a) adding an inflammatory cytokine to a culture containing mesenchymal stem cells, and confirming that the mesenchymal stem cells express CX3CL1; and/or b) confirming that 90% or more of the mesenchymal stem cells express EGFR and/or ITGA4.Type: ApplicationFiled: November 9, 2018Publication date: November 5, 2020Applicants: Sapporo Medical University, Nipro CorporationInventors: Osamu HONMOU, Yoshihiro YOSHIKAWA, Ryo TOMII, Masafumi YAO, Yukari NISHII, Yusuke WAGATSUMA
-
Patent number: 10640749Abstract: Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.Type: GrantFiled: May 28, 2015Date of Patent: May 5, 2020Assignees: NC MEDICAL RESEARCH INC., ASKA PHARMACEUTICAL CO., LTD., MITSUI SUMITOMO INSURANCE CARE NETWORK CO., LTD.Inventors: Osamu Honmou, Kazuo Hashi, Teiji Uede
-
Patent number: 10563173Abstract: To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.Type: GrantFiled: May 15, 2017Date of Patent: February 18, 2020Assignee: Nipro CorporationInventors: Osamu Honmou, Yoshihiro Yoshikawa, Naomi Morikawa
-
Publication number: 20190255118Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.Type: ApplicationFiled: May 6, 2019Publication date: August 22, 2019Applicant: Sapporo Medical UniversityInventor: Osamu Honmou
-
Publication number: 20190227067Abstract: [Problem] The present invention addresses the problem of providing a novel biomarker which makes it possible to find the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability of glioma cells and the like and also makes it possible to detect the prognosis, the risk, the invasion ability or the like in an earlier stage of a therapy of glioma. [Solution] The present invention relates to a method for evaluating the prognosis of glioma, said method comprising the steps of: detecting ACTC1 protein and/or mRNA encoding the protein in a glioma-containing sample collected from a patient; and determining that the prognosis of the glioma is poor when the ACTC1 protein and/or the mRNA encoding the protein is detected in the aforementioned step. According to the present invention, the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability and the like can be evaluated using a novel biomarker, i.e., ACTC1 protein and/or mRNA encoding the protein.Type: ApplicationFiled: July 28, 2016Publication date: July 25, 2019Applicant: SAPPORO MEDICAL UNIVERSITYInventors: Osamu HONMOU, Masahiko WANIBUCHI, Shunya OHTAKI, Masanori SASAKI, Yuko SASAKI, Nobuhiro MIKUNI
-
Patent number: 10328102Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.Type: GrantFiled: June 8, 2017Date of Patent: June 25, 2019Assignee: SAPPORO MEDICAL UNIVERSITYInventor: Osamu Honmou
-
Publication number: 20190183937Abstract: The present invention relates to a life extension agent containing CD24-negative mesenchymal stem cells and the treatment of dementia, cerebral infarction, spinal cord injury and the like using the life extension agent.Type: ApplicationFiled: April 13, 2017Publication date: June 20, 2019Applicants: Sapporo Medical University, Nipro CorporationInventors: Osamu Honmou, Masanori Sasaki, Yuko Sasaki, Rie Maezawa, Shinichi Oka, Masahito Nakazaki
-
Publication number: 20190117700Abstract: The present invention relates to a synapse formation promoter and a brain plasticity promoter comprising CD24-negative mesenchymal stem cells prepared from a patient's own bone marrow aspirate and treatment of dementia, chronic-phase cerebral infarction, chronic-phase spinal cord injury, mental diseases, and the like using the synapse formation promoter and brain plasticity promoter.Type: ApplicationFiled: April 26, 2017Publication date: April 25, 2019Applicants: Sapporo Medical University, Nipro CorporationInventors: Osamu Honmou, Masanori SASAKI, Rie MAEZAWA, Shinichi OKA, Yuko SASAKI, Masahito NAKAZAKI, Toshihiko YAMASHITA
-
Publication number: 20190002833Abstract: Provided is new means for reducing risk of cerebral hemorrhage associated with a reperfusion therapy for vessel occlusion (for example, administration of a medicament including a thrombolytic agent, a platelet aggregation inhibitor, and an anticoagulant agent, or physical removal of a blood clot) and treating an ischemic vascular disorder more effectively. The present invention relates to a medicament for treating an ischemic vascular disorder, comprising mesenchymal stem cells, wherein the medicament is used in combination with a reperfusion therapy for vessel occlusion and more specifically, to a medicament for treating an ischemic vascular disorder, wherein the medicament reduces risk of cerebral hemorrhage associated with the reperfusion therapy for vessel occlusion and extends a time window in which the therapy is applicable.Type: ApplicationFiled: December 26, 2016Publication date: January 3, 2019Applicants: Sapporo Medical University, Nipro CorporationInventors: Osamu Honmou, Masahito Nakazaki, Masanori Sasaki, Yuko Sasaki, Shinichi Oka
-
Publication number: 20170313984Abstract: To provide an autoserum-containing bone marrow cell culture system, whereby bone marrow cells, which are collected from a subject without using an anticoagulant, are subjected to an anticoagulation treatment using a medium in a liquid-tight state, cultured and then further cultured using the serum of said subject which is prepared in a liquid-tight state; an autoserum-containing bone marrow cell culture method; and a method for producing a medicinal composition which comprises, as the active ingredient, autoserum-containing cultured bone marrow cells. [Solution] An autoserum-containing bone marrow cell culture system for culturing bone marrow cells, which are collected from a subject without using an anticoagulant, using the serum of said subject, said system comprising a bone marrow cell suspension-storing device, a collected blood-storing device, an autoserum-acquiring device, and a bone marrow cell-culturing device.Type: ApplicationFiled: May 15, 2017Publication date: November 2, 2017Applicant: SAPPORO MEDICAL UNIVERSITYInventors: Osamu HONMOU, Yoshihiro Yoshikawa, Naomi Morikawa
-
Publication number: 20170266234Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.Type: ApplicationFiled: June 8, 2017Publication date: September 21, 2017Applicant: Sapporo Medical UniversityInventor: Osamu Honmou
-
Patent number: 9700582Abstract: The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.Type: GrantFiled: September 10, 2008Date of Patent: July 11, 2017Assignee: Sapporo Medical UniversityInventors: Osamu Honmou, Kiyohiro Houkin
-
Patent number: D836210Type: GrantFiled: July 14, 2017Date of Patent: December 18, 2018Assignees: NIPRO CORPORATION, SAPPORO MEDICAL UNIVERSITYInventors: Osamu Honmou, Tomohiro Uchimura, Kei Matsuo, Yoshihiro Yoshikawa, Yoshihito Yamagata, Masayuki Ishigami